Clinical trials: Psychiatric Illness
Alzheimer's Disease, Huntington Disease
A Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine)
This study will evaluate four different modified release formulation to estimate the amount of dimebon available to the body relative to the current dimebon formulation that is given three times a day.
- Trial name
- NCT00988624
- Testing
- Dimebon IR Tablet, Dimebon MR1, Dimebon MR2
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Pfizer
Major Depressive Disorder
Leveraging EEG for Antidepressant Prediction With Duloxetine and Bupropion
The LEAP-DB study will be conducted to validate the utility of EEG biomarkers as an aid to antidepressant treatment selection in adults with MDD.
- Trial name
- LEAP-DB (NCT04388189)
- Testing
- Duloxetine, Bupropion
- Sponsor
- Alto Neuroscience
Schizophrenia
Treatment on Iatrogenic Weight Gain and Dyslipidaemia Associated With Olanzapine
Olanzapine is one of the most effective and best tolerated of the atypical antipsychotics, but it is also particularly associated with weight gain and metabolic problems.
- Trial name
- GWMD09126 (NCT01491490)
- Testing
- GWP42003 : GWP42004 (40:1)
- Where
- 6 sites in United Kingdom
- Volunteers
- 2 people
- Sponsor
- GW Research Ltd
Alzheimer's Disease
A 12-week Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type
Active treatment extension study of the 331-14-213 trial, to assess the long-term safety and tolerability of oral brexpiprazole as treatment in adult participants with agitation associated with dementia of the Alzheimer's type…
- Trial name
- NCT03594123
- Testing
- Brexpiprazole
- Where
- United States
- Volunteers
- 259 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With Schizophrenia
The purpose of this study is to evaluate the efficacy of paliperidone palmitate 3 month formulation (PP3M) compared with placebo in delay of the time to first occurrence of relapse of the symptoms of schizophrenia.
- Trial name
- NCT01529515
- Testing
- PP3M 175 mg eq., PP3M 263 mg eq., PP3M 350 mg eq.
- Where
- 53 sites in United States, Colombia and 6 more
- Volunteers
- 509 people
- Sponsor
- Janssen Research & Development, LLC
Attention-Deficit Hyperactivity Disorder(ADHD)
A Trial to Evaluate the Efficacy and Safety of EB-1020 in Pediatric Patients With ADHD
The purpose of this study is to evaluate the efficacy and examine the safety of two doses of EB-1020 QD XR capsule administered once daily orally in pediatric ADHD patients.
- Trial name
- NCT07086313
- Testing
- EB-1020 (Centanafadine) low dose, EB-1020 (Centanafadine) high dose
- Where
- Japan
- Volunteers
- 315 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Healthy Participants, Narcolepsy
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-925 in Healthy Volunteers and Participants With Narcolepsy
The purpose of this study is to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-925 when administered to healthy participants and narcolepsy participants.
- Trial name
- NCT03748979
- Testing
- TAK-925
- Where
- 3 sites in Japan
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Takeda
Substance Dependence
To Investigate If Single Doses Of GSK618334 Are Safe And To Investigate Blood Levels Of GSK618334
GSK618334 is being developed as an innovative treatment for substance dependence and potentially other compulsive behavioral disorders.
- Trial name
- NCT00513279
- Testing
- GSK618334
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Alzheimer Disease, Cognition Disorders
Investigation Into Delay to Diagnosis of Alzheimer's Disease With Exelon (InDDEx)
This phase IIIb trial is a prospective, randomized, double-blind, placebo-controlled, 36-month study comparing the length of time of progression from mild cognitive impairment (MCI) to a clinical diagnosis of Alzheimer's disease…
- Trial name
- NCT00000174
- Testing
- Rivastigmine
- Where
- 15 sites in United States
- Sponsor
- Novartis
Alzheimer's Disease
Safety Study of MT-4666 in Subjects With Alzheimer's Disease
The objective of this study is to evaluate the safety and efficacy of 2 fixed dose of MT-4666 administered once daily for 52 weeks with or without receiving a concomitant acetylcholinesterase inhibitors (AChEIs), in patients with…
- Trial name
- NCT02327182
- Testing
- MT-4666
- Where
- Japan
- Volunteers
- 117 people
- Sponsor
- Tanabe Pharma Corporation
Dementia, Alzheimer's Disease
Use of Different Treatment Care Methods in Patients With Dementia Associated With Alzheimer's Disease
The purpose of this observational study is to examine patterns of treatment care for patients with Alzheimer's disease (AD) in a real-world arena and to examine the association with different outcomes for patients and informal…
- Trial name
- REMIND (NCT00283725)
- Testing
- No intervention
- Volunteers
- 573 people
- Sponsor
- Ortho-McNeil Neurologics, Inc.
Substance-related Disorders, Alcohol and Other Substance Use Prevention
Evaluating Feasibility, Acceptability, Usability, and an Initial Estimate of Effect of a Novel Training Platform on Peer Recovery Supporter Skill, Adherence, and Knowledge Gain-Phase I
This pilot study evaluates the feasibility, usability, and acceptability of the Thrive Digital Peer Platform (TDPP), an online training system for Peer Recovery Support Specialists (PRSS).
- Conditions
- Substance-related Disorders, Alcohol and Other Substance Use Prevention, Alcohol and Other Drug Use Disorders
- Trial name
- NCT07090590
- Testing
- Thrive Digital Peer Platform (TDPP)
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Thrive Digital Health, LLC
Chronic Pain
CANPAIN Feasibility Study Pragmatic Real World Trial Investigating CBMP in Chronic Pain Patients
The CANPAIN study has been devised to evaluate the efficacy and safety of a defined cannabis based medicinal product (CBMP) delivered by inhalation to patients with non cancer chronic pain attending a private clinic.
- Trial name
- CANPAIN (NCT05288010)
- Testing
- Cannabis
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- Harley Street (CPC) Limited
Sleep Disorders
Clinical Trial of the Safety and Tolerability of the Drug MMH-450 in Healthy Volunteers
Open-label, non-comparative, non-randomized clinical trial of the safety and tolerability of the drug MMH-450 in healthy volunteers
- Trial name
- NCT07708623
- Testing
- MMH-450
- Where
- Russia
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Materia Medica Holding
Sleep Disturbance, Stress
GUT-FEELINGS: Using Citizen Science for Large-Scale Prebiotic Clinical Trials for Mental Wellness in Adults
The goal of this study is to evaluate the effects of different products in participants experiencing feelings of anxiety. The main question it aims to answer is: Do these products affect feelings of anxiety and related wellness…
- Conditions
- Sleep Disturbance, Stress, Feeling Anxious
- Trial name
- NCT07752823
- Testing
- Active Gut Feeling Product 1, Active Gut Feeling Product 2
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Holobiome, Inc.
Binge-Eating Disorder
A Study to Assess the Long-term Safety and Efficacy of Solriamfetol in Subjects With Binge Eating Disorder
This is a Phase 3, multi-center, open-label and randomized withdrawal study to evaluate the long-term safety and efficacy of solriamfetol in the treatment of binge eating disorder (BED) in adults.
- Trial name
- NCT06878976
- Testing
- Solriamfetol
- Where
- 33 sites in United States
- Volunteers
- 236 people
- Sponsor
- Axsome Therapeutics, Inc.
Schizophrenia
A Pharmacokinetics and Pharmacodynamics Study Under Fasting and Fed Conditions With Paliperidone Extended-release and Immediate-release Formulations
The purpose of this study is to compare the bioavailability of 2 extended release paliperidone pellet formulations under fasting and fed conditions with a 2 mg paliperidone oral solution under fasting conditions.
- Trial name
- NCT00796640
- Testing
- ER Paliperidone
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
The Safety and Efficacy of Lurasidone In Subjects With Schizophrenia Switched From Olanzapine
An open-label, single-arm and multi-center study for 16 weeks
- Trial name
- NCT05213143
- Testing
- Lurasidone
- Where
- China
- Volunteers
- 13 people
- Sponsor
- Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
Major Depressive Disorder
Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder
The study will assess efficacy, safety and tolerability of 0.5 mg/day and 1 mg/day of sublingual (under the tongue) formulation of agomelatine in patients with Major Depressive Disorder.
- Trial name
- NCT01110889
- Testing
- Agomelatine (AGO178C)
- Where
- 48 sites in United States, Puerto Rico
- Volunteers
- 582 people
- Sponsor
- Novartis Pharmaceuticals
Insomnia
A Long Term Safety Study of Suvorexant in Participants With Primary Insomnia (MK-4305-009 AM3)
This study will establish the safety and tolerability of suvorexant (MK-4305) when administered for up to 14 months. Participants will be randomized to receive suvorexant or placebo for a 12-month double-blind (DB) Treatment…
- Trial name
- NCT01021813
- Testing
- Suvorexant
- Volunteers
- 781 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.